Patents by Inventor Martin J. Oliver

Martin J. Oliver has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10314785
    Abstract: The present invention provides a method for the sterilization of a labile glucocorticosteroid, which method comprises heat-treating by moist heat the labile glucocorticosteroid in the form of a suspension for a sterilizing-effective time. The methods and compositions according to the invention are useful as therapeutic tools to prevent, reverse, and/or reduce the symptoms of allergic and/or inflammatory conditions in a mammalian patient. The invention also provides methods and compositions, which may be manipulated and fine-tuned to fit the condition(s) to be treated while producing fewer side effects.
    Type: Grant
    Filed: June 20, 2014
    Date of Patent: June 11, 2019
    Assignee: NORTON HEALTHCARE LTD
    Inventors: Adrian Ashley, Paul Lamb, Donald MacDonald, John Miller, Martin J. Oliver, Mathew Pollard
  • Publication number: 20140370097
    Abstract: The present invention provides a method for the sterilization of a labile glucocorticosteroid, which method comprises heat-treating by moist heat the labile glucocorticosteroid in the form of a suspension for a sterilizing-effective time. The methods and compositions according to the invention are useful as therapeutic tools to prevent, reverse, and/or reduce the symptoms of allergic and/or inflammatory conditions in a mammalian patient. The invention also provides methods and compositions, which may be manipulated and fine-tuned to fit the condition(s) to be treated while producing fewer side effects.
    Type: Application
    Filed: June 20, 2014
    Publication date: December 18, 2014
    Inventors: Adrian Ashley, Paul Lamb, Donald MacDonald, John Miller, Martin J. Oliver, Mathew Pollard
  • Patent number: 8791096
    Abstract: The present invention provides a method for the sterilization of a labile glucocorticosteroid, which method comprises heat-treating by moist heat the labile glucocorticosteroid in the form of a suspension for a sterilizing-effective time. The methods and compositions according to the invention are useful as therapeutic tools to prevent, reverse, and/or reduce the symptoms of allergic and/or inflammatory conditions in a mammalian patient. The invention also provides methods and compositions, which may be manipulated and fine-tuned to fit the condition(s) to be treated while producing fewer side effects.
    Type: Grant
    Filed: May 17, 2005
    Date of Patent: July 29, 2014
    Assignee: Norton Healthcare Ltd
    Inventors: Adrian Ashley, Paul Lamb, Donald MacDonald, John Miller, Martin J. Oliver, Mathew Pollard
  • Publication number: 20080139519
    Abstract: The present invention provides a method for the sterilization of a labile glucocorticosteroid, which method comprises heat-treating by moist heat the labile glucocorticosteroid in the form of a suspension for a sterilizing-effective time. The methods and compositions according to the invention are useful as therapeutic tools to prevent, reverse, and/or reduce the symptoms of allergic and/or inflammatory conditions in a mammalian patient. The invention also provides methods and compositions, which may be manipulated and fine-tuned to fit the condition(s) to be treated while producing fewer side effects.
    Type: Application
    Filed: May 17, 2005
    Publication date: June 12, 2008
    Inventors: Adrian Ashley, Paul Lamb, Donald MacDonald, John Miller, Martin J. Oliver, Mathew Pollard
  • Publication number: 20040197273
    Abstract: A pharmaceutical suspension aerosol formulation containing HFA-227 as a propellant.
    Type: Application
    Filed: April 9, 2004
    Publication date: October 7, 2004
    Applicant: 3M COMPANY
    Inventors: Robert K. Schultz, David W. Schultz, Martin J. Oliver, Robert A. Moris, Philip A. Jinks
  • Patent number: 6743413
    Abstract: Pharmaceutical suspension aerosol formulations containing a therapeutically effective amount of a drug and HFC 134a, HFC 227, or a mixture thereof.
    Type: Grant
    Filed: May 31, 1995
    Date of Patent: June 1, 2004
    Assignee: 3M Company
    Inventors: Robert K. Schultz, David W. Schultz, Martin J. Oliver, Robert A. Moris, Philip A. Jinks
  • Publication number: 20040013611
    Abstract: Pharmaceutical suspension aerosol formulations containing a therapeutically effective amount of a drug and HFC 134a, HFC 227, or a mixture thereof.
    Type: Application
    Filed: July 9, 2003
    Publication date: January 22, 2004
    Applicant: Minnesota Mining and Manufacturing Company, now 3M Company
    Inventors: Robert K. Schultz, David W. Schultz, Martin J. Oliver, Robert A. Moris, Philip A. Jinks
  • Publication number: 20030103907
    Abstract: Pharmaceutical suspension aerosol formulations containing a therapeutically effective amount of a drug and HFC 134a, HFC 227, or a mixture thereof.
    Type: Application
    Filed: August 8, 2002
    Publication date: June 5, 2003
    Inventors: Robert K. Schultz, David W. Schultz, Martin J. Oliver, Robert A. Moris, Philip A. Jinks
  • Patent number: 6264923
    Abstract: A pharmaceutical aerosol formulation suitable for oral and/or nasal inhalation including an anti-inflammatory steroid of the formula in which: R1 is 1-butyl, 2-butyl, cyclohexyl or phenyl and R2 is acetyl or isobutanoyl, in particular ciclesonide. The formulations also include hydrofluorocarbon propellants such as HFC 134a and/or 227, and cosolvent such as ethanol in an amount sufficient to solubilize the ciclesonide or related steroid (and various optional ingredients, such as surfactant). The formulations exhibit very desirable physical and chemical stability, as well as excellent delivery characteristics.
    Type: Grant
    Filed: November 15, 1999
    Date of Patent: July 24, 2001
    Assignee: 3M Innovative Properties Company
    Inventors: Martin J. Oliver, Kanu M. Fatania, John S. Scott, Helgert Muller
  • Patent number: 6120752
    Abstract: A pharmaceutical aerosol formulation suitable for oral and/or nasal inhalation including an anti-inflammatory steroid of the formula ##STR1## in which: R.sub.1 is 1-butyl, 2-butyl, cyclohexyl or phenyl andR.sub.2 is acetyl or isobutanoyl, in particular ciclesonide. The formulations also include hydrofluorocarbon propellants such as HFC 134a and/or 227, and cosolvent such as ethanol in an amount sufficient to solubilize the ciclesonide or related steroid (and various optional ingredients, such as surfactant). The formulations exhibit very desirable physical and chemical stability, as well as excellent delivery characteristics.
    Type: Grant
    Filed: May 13, 1998
    Date of Patent: September 19, 2000
    Assignees: 3M Innovative Properties Company, Byk Gulden Lomberg Chemische Fabrik GmbH
    Inventors: Martin J. Oliver, Kanu M. Fatania, John S. Scott, Helgert Muller
  • Patent number: 6054488
    Abstract: A pharmaceutical suspension formulation suitable for aerosol administration having from 0.0025 to 0.1% w/w of micronized Formoterol, or an acid addition salt thereof, from 0.1 to 5.0% w/w ethanol, HFA 134a, HFA 227 or a mixture of HFA 227 and HFA 134a, and optionally a surfactant other than a monoacetylated or diacetylated monoglyceride, the formulation being further characterized in that it exhibits substantially no growth in particle size or change in crystal morphology of the drug over a prolonged period, is substantially and readily redispersible, and upon redispersion does not flocculate so quickly as to prevent reproducible dosing of the drug.
    Type: Grant
    Filed: June 2, 1998
    Date of Patent: April 25, 2000
    Assignee: 3M Innovative Properties Company
    Inventors: Martin J. Oliver, Simon G. Paling, Philip A. Jinks, Sukhbinder K. Jaiswal
  • Patent number: 4827208
    Abstract: In circuit testers, notably automatic test equipment for the in circuit testing of digital devices, overheating damage can result if outputs are repeatedly "overdriven", that is, while applying a test input to a first device, an output of a second connected device is forced into a state contrary to that it would normally adopt. Damage is avoided by enforcing a cooling interval between overdriving tests based upon a list of parameters representative of the overdriven device and its environment. In order to reduce the overall test time, a parameter is based on a measurement derived from a circuit of the type under test. A first test results in device heating to a value. A cooling interval is enforced so that a subsequent test which results in further heating of the device, may be made without exceeding device maximum allowable temperature .sup.T max.
    Type: Grant
    Filed: February 12, 1987
    Date of Patent: May 2, 1989
    Assignee: Membrain Limited
    Inventors: Martin J. Oliver, Kevin E. Brazier, Stephen R. Boote
  • Patent number: 4727317
    Abstract: Part of a printed circuit board circuit is made up of three gates (30, 31, 32) each of which are formed on a different device and interconnected by the board print so that connections (35, 36) may be established by means of probes. Associated with the inputs and outputs of each device are phantom diodes (such as diode 32) which are normally connected to circuit ground (38) but which in the case of one gate (31) are connected the supply rail (37), the device of which it forms part having been mounted in the board in the wrong orientation. By the steps of connecting one device power input pin to a test ground potential (38), raising the potential of the other power input pin via connection to a supply rail (37) and lowering the potential of an active pin (33) a diode (302) may be made to conduct current via path (304) indicating that the device (31) is wrongly orientated. The applied low potential is insufficient to bring correctly connected diodes (such as that of device 30) into conduction.
    Type: Grant
    Filed: November 7, 1985
    Date of Patent: February 23, 1988
    Assignee: Membrain Ltd.
    Inventor: Martin J. Oliver